Unmasking the Diabetes Epidemic in India (2023): Prevalence, Complications & Strategies for Effective Management

Introduction & Background:

A recent study conducted by Das AK et al. involves Indian patients and analyzes the management algorithm of diabetes in India, along with the various complications associated with the disease.


Study Type:

Multi-centric, Observational, Prospective, trial.

Inclusion criteria:

Adults aged ≥25 to ≤60 years diagnosed with T2DM (duration ≥2 years at enrollment) and controlled/uncontrolled on ≥2 anti‐diabetic agents.

Number of Patients:



Microvascular complications like Neuropathy and/or Retinopathy and/or Nephropathy were observed in around 18% of patients. Macrovascular complications like non‐fatal MI, non‐fatal stroke, CV death and peripheral vascular disease [PVD] were observed in around 3% of patients. Microvascular complications were significantly higher in Non-Metropolitan cities compared to Metropolitan cities. The most common CV risk factors associated with Diabetes were found to be Hypertension followed by Dyslipidemia. Around 12% of patients starting with Initial therapy of Insulin added one or the other Oral Anti-diabetic Drugs. Biguanides and sulfonylureas are the most commonly prescribed Oral Anti-diabetic Drugs followed by an emergence of Dipeptidyl Peptidase-IV Inhibitor (DPP-4i).

My point of view: India is facing an epidemic of Diabetes. To control this epidemic Early detection with Proper Management is utterly important. Few of the Global guidelines now outlines the importance of Early detection in Diabetes to not only Manage the disease but also prevent its further Complications.

Reference: Das AK et.al. Two-year trends from the LANDMARC study: A 3-year, pan-India, prospective, longitudinal study on the management and real-world outcome in patients with type 2 diabetes mellitus. Endocrinol Diabetes Metab. 2023 Mar;6(2):e404.

For more detail reading visit: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000633/

More to read on Diabetes and its complications: https://pubmed.ncbi.nlm.nih.gov/31855345/

More to feed: https://insightfulthinker.com/after-tomato-prices-its-time-for-tomato-flu-to-take-a-rise/

Leave a comment

Follow by Email